Bone Abstracts

Hypogonadism is common in cardiac transplant (CTX) patients and exerts negative effects on bone but also on libido and quality of life.We investigated whether testosterone replacement therapy (TRT) has any positive effects on bone mass, fracture incidence, and quality of sex life when administered in addition to ibandronate (IBN) in hypogonadal CTX recipients. 52 male patients entered the study and received IBN (quarterly 2 μg i.v.). 60% of the pati...

Objectives: The ketogenic diet (KD) is a medically supervised, high fat, low carbohydrate and restricted protein diet which has been used successfully in patients with refractory epilepsy. Only one published report has explored its effect on the skeleton. We postulated that KD impairs bone mass accrual and examined skeletal health parameters in this patient group.Methods: Patients commenced on the KD from 2002–2009 were enrolled in a prospective, lo...

Objective: Although metabolic syndrome is common in gout patients, recent reports that bone mineral density may actually be reduced (and falls common) in this group have led researchers to hypothesise that osteoporotic fracture may be more common in subjects with gout than in healthy controls. We tested this hypothesis in a national Danish registry.Material and Methods: We identified subjects as new users of allopurinol, a proxy for gout, for the years 1...

see PP351....

In type 2 diabetes mellitus (T2DM) patients, an increased fracture risk is observed, although the bone mineral density is even higher than in non-diabetic patients, which raises the question of the quality of the organic and inorganic matrix in bone1,2. T2DM is also known to favor inflammation of the gingiva and paradontosis in general. However, little is known about the mineral nano-architecture in the mandible and about the possible influence of diabetes. Using sy...

Introduction: Elevated FGF-23 serum levels are induced by hyperphosphatemia and are linked to poor skeletal mineralization and adverse outcomes including vascular calcification and mortality. Recently, it was shown that FGF-23 levels are substantially elevated in acute kidney injury (AKI), and that higher levels in AKI are associated with a greater risk of adverse outcomes.Methods: In 25 vitamin D deficient (25(OH)D <20 ng/ml) critically ill adults w...

Background and objective: Targeting bone and cartilage includes approaches using tetracyclines, peptide conjugates, as well as anionic moieties like bisphosphonates. However, the selective targeting of the different compartments still remains a challenge. In previous studies native and demineralized ovine bone was used to analyze the affinity of polyanions derived from dendritic polyglycerol (dPG) toward hydroxyapatite and collagen. Whereas the neutral polymer did not show any...

Introduction: Effective treatment of postmenopausal osteoporosis (PMO) is frequently compromised by poor adherence to short-term (≤1-monthly) medications. Aim of this study is to investigate the effect of parenteral ibandronate (IBN) compared to denosumab in a cohort of IBN pretreated PMO patients.Methods: In a retrospective analysis, a total of 808 women were treated with quarterly 3 mg IBN injections for 27+3 months and were regularly mo...

Abaloparatide (BA058) is a synthetic analog of PTHrP1–34 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

Background: Hypercalcaemia secondary to malignancy is rare in children and adolescents. Parathyroid hormone related peptide (PTH-rP) secreted by malignant cells increases bone resorption and renal calcium retention causing hypercalcaemia. We report two cases of hypercalcaemia of malignancy refractory to treatment with pamidronate and corticosteroids but responsive to treatment with Denosumab and Zoledronic acid.Case 1: Presenting problem: A 17-year-old b...